Darius H, Erbel R, Rupprecht H J, Pop T, Meyer J
II. Medizinische Klinik, Johannes-Gutenberg-Universität Mainz.
Med Klin (Munich). 1990 Feb;85 Suppl 1:23-6.
The effects of the molsidomine metabolite SIN-I (0.5 mg) on tolerance to ischemia were studied in twelve patients during coronary angioplasty of the LAD. SIN-I resulted in a significant prolongation of time to ST-segment alteration one, five and ten minutes after intracoronary injection. Beside hemodynamic reasons the effects of SIN-I on circulating blood cells and collateral perfusion are discussed as mechanisms of action. The effects of molsidomine (2 X 8 mg/d) on restenosis rate after initially successful coronary angioplasty were studied in 393 patients in a prospective, randomized and controlled trial. 29% of patients treated with molsidomine experienced restenosis at control coronary angiography at six months. The control group receiving nifedipine (3 X 20 mg/d) and acetylsalicylic acid (1 X 500 mg/d) showed a restenosis in 33% of patients. Therefore, molsidomine seems as effective as nifedipine and acetylsalicylic acid in treating patients after coronary angioplasty.
在12例接受左前降支冠状动脉血管成形术的患者中，研究了吗多明代谢产物SIN-I（0.5毫克）对缺血耐受性的影响。冠状动脉内注射后1、5和10分钟，SIN-I显著延长了ST段改变的时间。除血流动力学原因外，还讨论了SIN-I对循环血细胞和侧支循环灌注的影响作为其作用机制。在一项前瞻性、随机对照试验中，对393例患者研究了吗多明（2×8毫克/天）对初次成功冠状动脉血管成形术后再狭窄率的影响。接受吗多明治疗的患者中，29%在6个月时冠状动脉造影复查时出现再狭窄。接受硝苯地平（3×20毫克/天）和乙酰水杨酸（1×500毫克/天）的对照组有33%的患者出现再狭窄。因此，吗多明在治疗冠状动脉血管成形术后的患者方面似乎与硝苯地平和乙酰水杨酸一样有效。
